ERBB2 and breast carcinoma: These findings suggest that a high proportion of patients with metastatic ERBB2-positive breast cancer and TNBC will require radiotherapy for BRM; varying incidence and time to development of BRM by breast cancer subtype could inform future BRM screening programs.